| Literature DB >> 33432066 |
Yuki Nakamura1, Shozo Yokoyama2, Kenji Matsuda1, Koichi Tamura1, Yasuyuki Mitani1, Hiromitsu Iwamoto1, Yuki Mizumoto1, Daisuke Murakami1, Yuji Kitahata1, Hiroki Yamaue1.
Abstract
Preoperative ctDNA status in relation to recurrence in cases of CRC remains unclear. We examined preoperative ctDNA detection by targeting KRAS gene mutations as a predictive marker for recurrence after CRC surgery. We measured the preoperative KRAS mutated ctDNA status and analyzed the correlation with clinicopathologic features of 180 patients that underwent surgery for CRC. We studied the association between preoperative KRAS mutated ctDNA and postoperative recurrence in patients (n = 150) that underwent radical surgery. KRAS mutated ctDNA was detected in 59 patients (32.8%). Median mutant allele frequency of KRAS in ctDNA was 0.20%. KRAS status in ctDNA and lymph node metastasis and distant metastasis were not significantly different. Among patients that underwent radical resection, recurrence occurred in 21 (14.0%, median follow-up 24 months). In Kaplan-Meier analysis, preoperative detection of KRAS mutated ctDNA was associated with inferior recurrence-free interval (RFI) (p = 0.002) and recurrence-free survival (RFS) (p = 0.025). In a multivariate Cox proportional hazards model, preoperative detection of KRAS mutated ctDNA was an independent factor related to both RFI (HR = 3.08; p = 0.012) and RFS (HR = 2.18; p = 0.044). Preoperative measurement of KRAS mutated ctDNA could be useful to decide postoperative treatment.Entities:
Year: 2021 PMID: 33432066 PMCID: PMC7801374 DOI: 10.1038/s41598-020-79909-4
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379